Brief: Mainz Biomed Expands Coloalert Commercialization With Ganzimmun Diagnostics In Europe
14/12/2021 08:03
Dec 14 (Reuters) - MAINZ BIOMED BV 4TO.F :
* EXPANDS COLOALERT COMMERCIALIZATION WITH GANZIMMUN
DIAGNOSTICS
IN EUROPE
* GANZIMMUN DIAGNOSTICS HAS INTERDISCIPLINARY TEAM OF OVER
370
MEDICAL TECHNICAL ASSISTANTS, PHYSICIANS, CHEMISTS, BIOLOGISTS,
AND NUTRITIONISTS WHO PROCESS APPROXIMATELY 5,500 LABORATORY
ORDERS DAILY
Source text for Eikon: ID:nEQ3BVbtFa
Further company coverage: 4TO.F
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on Quantum Cyber NV
See all newsBrief: Quantum Cyber To Proceed With Pending Litigation Against Adam Gefvert
Brief: Quantum Cyber NV Files Lawsuit Against White Diamond Research, Adam Gefvert And Stocktwits, Inc. In New York Supreme Court
Quantum Cyber jumps on SpaceX stake purchase plan
Brief: Quantum Cyber Signs Loi To Acquire An Estimated 43,000 Square Foot U.S.-Based Manufacturing Facility To Support Mass-Scale Autonomous Drone Production
Brief: Quantum Cyber NV - To Terminate ATM Sales Agreement With Maxim Effective June 7, 2026 - SEC Filing